Design, Development, And Evaluation of a Pulsatile Drug Delivery System for Rimegepant

Indrayani Satpute[1], Prof. Vinayak S Munde[2]
[1]*Student, M. Pharm 2nd Yr., Department of Pharmaceutics, Dr. Vedprakash Patil Pharmacy College, Chh. Sambhajinagar*
[2]*Professor, Department of Pharmaceutics, Dr. Vedprakash Patil Pharmacy College, Chh. Sambhajinagar*

***Abstract*—Pulsatile drug delivery systems (PDDS) are advanced controlled-release platforms engineered to release an active pharmaceutical ingredient (API) after a predetermined lag time, followed by a rapid drug release phase. This time-specific release pattern is advantageous for conditions that follow circadian rhythms or require drug action at specific physiological times. *Rimegepant* is a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist used in the acute and preventive treatment of migraine, where immediate and timely release could enhance therapeutic outcomes. This review synthesizes existing pulsatile delivery methodologies with rimegepant's pharmacological properties and discusses potential formulation strategies, design considerations, and evaluation criteria for future PDDS of rimegepant.**

***Index Terms*—Pulsatile drug delivery systems, Rimegepant, Mechanism of PDDS, Rationale for Pulsatile Delivery of Rimegepant.**

I. INTRODUCTION

Pulsatile drug delivery systems (PDDS) are advanced drug delivery platforms specifically designed to release a therapeutic agent at a predetermined time or site, rather than continuously. Unlike conventional sustained-release formulations that maintain relatively constant plasma drug levels, PDDS is characterized by a controlled lag period followed by a rapid or "burst" release of the drug. This controlled timing allows the drug to be delivered in synchronization with the body's biological rhythms or the specific pathophysiological needs of a disease, thereby enhancing therapeutic outcomes and reducing unwanted side effects.[1]

Mechanism of PDDS

1. Lag Phase (No Release Period):

- The drug remains largely inactive or minimally released during this initial period.
- The lag time can be adjusted by modifying coating thickness, polymer composition, or capsule design.
- This phase ensures that the drug is released only when required, which is particularly useful for diseases with predictable timing of symptoms (e.g., early morning migraines or nocturnal asthma).[2]

2. Burst Release Phase:

- After the lag period, the system rapidly releases the drug, achieving therapeutic plasma concentration quickly.
- The burst can be triggered by mechanisms such as polymer erosion, swelling, osmotic pressure, or environmental pH changes.[3]

This controlled temporal delivery makes PDDS especially suitable for chronotherapy, where the timing of drug administration is as critical as the dose itself.

Key Advantages of PDDS

- Synchronization with Biological Rhythms (Chrono therapeutics):

PDDS can align drug release with the natural circadian patterns of diseases. For instance, cardiovascular events often occur in the early morning, and migraines frequently peak after waking; PDDS ensures drug availability at these critical times.[4]

- Enhanced Efficacy for Time-Dependent Conditions:

By delivering the drug exactly when it is needed, PDDS maximizes therapeutic effects and prevents symptom onset.[5]

- Reduced Dosing Frequency and Improved Patient Compliance:

The timed-release profile reduces the need for multiple daily doses, making the therapy more convenient and adherence-friendly.[6]

- Reduced Systemic Side Effects:

Temporal control limits systemic exposure outside of the therapeutic window, reducing potential side effects associated with continuous drug levels.[7]

Common Designs of PDDS

1. Press-Coated Tablets:
- A core tablet containing the drug is coated with a polymeric layer that controls the lag time.
- The coating dissolves or erodes after the specified period, leading to rapid drug release.
- Advantages: Simple manufacturing and predictable lag times.[8]

2. Pulsincaps:
- Consist of a capsule body filled with the drug core and sealed with a hydrogel or wax plug.
- The plug dissolves or swells over time, releasing the drug in a burst.
- Commonly used for oral time-controlled delivery.[9]

3. Hydrogels:
- Polymers that swell in response to water, pH, or temperature, releasing the drug when triggered.
- Useful for controlled lag times and environment-sensitive release.[10]

4. Erosion-Controlled Systems:
- Drug is embedded in a matrix that gradually erodes, followed by rapid release after a specific lag period.
- Often employed for site-specific delivery, such as colon-targeted therapy.[11]

II. OVERVIEW OF RIMEGEPANT

Rimegepant



Rimegepant

Rimegepant is a novel, orally active calcitonin gene-related peptide (CGRP) receptor antagonist that has been approved for both acute treatment and preventive therapy of migraine in adults. As a small-molecule CGRP antagonist, it provides an alternative to traditional migraine therapies such as triptans, offering efficacy with a favorable safety profile.[12]

Pharmacological Mechanism

- CGRP Antagonism:

Rimegepant selectively binds to CGRP receptors, preventing CGRP from exerting its physiological effects.

- Pathophysiological Impact:

CGRP is a neuropeptide involved in neurogenic inflammation, vasodilation, and transmission of pain signals in migraine pathophysiology. By blocking CGRP activity, rimegepant reduces the neuroinflammatory cascade and mitigates vascular changes associated with migraine attacks.

- Clinical Relevance:

This mechanism allows rimegepant to target the underlying cause of migraine pain, rather than simply masking symptoms.[13]

Clinical Efficacy

- Acute Treatment:

In randomized clinical trials, a single 75 mg oral dose of rimegepant provided significant pain relief and freedom from the most bothersome migraine-associated symptom (MBS) within 2 hours' post-dose.

- Preventive Therapy:

Rimegepant has also demonstrated efficacy in reducing the frequency of migraine attacks when administered every other day, offering both acute relief and prophylactic benefits.

- Symptom Improvement:

The drug effectively alleviates associated symptoms, including nausea, photophobia, and phonophobia, contributing to enhanced quality of life for migraine patients.[14]

Dosage and Administration

- Acute Use: 75 mg orally, taken as needed at the onset of a migraine attack.
- Preventive Use: 75 mg orally, administered every other day, as recommended for migraine prevention.
- Formulations: Rimegepant is available in orally disintegrating tablets (ODTs) and conventional oral tablets, facilitating convenient dosing without the need for water intake (ODT) and rapid onset of action.[15]

Limitations of Conventional Delivery

Despite its proven efficacy, rimegepant's current delivery methods are limited to conventional oral tablets or ODTs, which release the drug immediately after ingestion. These conventional systems:

- Do not provide time-controlled or chronotherapeutic release, which could be beneficial given the circadian patterns of migraine attacks.
- Require patients to take the drug at the onset of symptoms, which may not always align with anticipated migraine timing.
- Offer limited control over therapeutic plasma concentrations, potentially leading to variability in efficacy or suboptimal prevention.[16]

Potential for Pulsatile Drug Delivery

Given the temporal nature of migraine attacks, rimegepant is an ideal candidate for a pulsatile drug delivery system (PDDS). A PDDS could:

- Release the drug at a specific time, e.g., early morning, coinciding with peak migraine risk.
- Maintain therapeutic drug levels during the window of anticipated migraine activity.
- Enhance patient convenience and compliance, reducing the need for on-demand dosing.

Such a system could transform rimegepant therapy from purely reactive treatment to proactive, chronotherapeutically optimized migraine management.[17]

III. RATIONALE FOR PULSATILE DELIVERY OF RIMEGEPANT

Migraine is a complex neurological disorder often characterized by recurring attacks that follow predictable temporal patterns. Clinical observations indicate that for many patients, migraine pain and associated symptoms frequently peak in the early morning hours, or at specific times related to lifestyle, sleep cycles, or hormonal fluctuations. These circadian patterns suggest that timing drug delivery to coincide with anticipated attacks could substantially enhance therapeutic outcomes.[18]

A pulsatile drug delivery system (PDDS) offers an innovative approach to optimize rimegepant therapy. By programming a lag time followed by rapid drug release, PDDS could release the drug precisely at the onset of anticipated migraine episodes, enabling both preventive and early intervention strategies. This temporal targeting is especially relevant for patients whose attacks are predictable, allowing for proactive management rather than purely reactive dosing.[19]

Advantages of PDDS for Rimegepant

1. Enhanced Onset of Action at Targeted Times:

- By releasing rimegepant at the most relevant physiological time such as upon waking when migraines often intensify PDDS can ensure rapid therapeutic plasma levels when they are most needed.
- This approach could improve pain relief, reduce attack severity, and enhance patient quality of life compared to conventional immediate-release tablets taken after symptoms appear.[20]

2. Reduced Unnecessary Systemic Exposure:

- Conventional dosing results in systemic drug exposure even during periods when migraine risk is low, potentially leading to unneeded pharmacological effects.
- PDDS limits drug release to high-risk windows, potentially reducing systemic side effects and improving safety.[21]

3. Improved Patient Compliance:

- Self-regulated timing in PDDS reduces the burden of on-demand dosing, which may be inconvenient or delayed during acute attacks.
- By embedding the timing into the delivery system, PDDS can simplify the treatment regimen, leading to better adherence and consistent therapeutic coverage.[22]

Supporting Evidence and Design Considerations
While no direct studies on pulsatile rimegepant delivery are currently indexed in the literature, research on PDDS for other chronotherapeutically relevant drugs such as anti-hypertensives, anti-asthmatics, and anti-inflammatory agents provides a solid foundation for design strategies.

Key insights include:
- Lag-time customization:

The system can be designed to release rimegepant after a specific delay, tailored to individual patient patterns or general circadian trends in migraine occurrence.

- Burst release optimization:

Ensuring rapid attainment of therapeutic plasma concentrations aligns with the acute symptom onset phase, improving clinical effectiveness.

- Polymer and matrix selection:

Time-controlled polymers, hydrogels, or erosion-controlled coatings used in other PDDS can be adapted to the physicochemical properties of rimegepant for precise temporal control.[23]
Collectively, these design strategies support the development of a rimegepant PDDS, which could transform migraine management from reactive treatment to predictive, chronotherapy-aligned intervention.

IV. DESIGN CONSIDERATIONS FOR PULSATILE RIMEGEPANT SYSTEMS

Developing a pulsatile drug delivery system (PDDS) for rimegepant requires careful consideration of multiple formulation and design aspects to ensure precise timing, rapid therapeutic effect, and patient safety. The primary goal is to synchronize drug release with expected migraine onset, enabling preventive or early-intervention therapy.[24]

4.1. Selection of Delivery Approach

The choice of delivery system is central to achieving the desired lag time and burst release profile. Common approaches include:

Press-Coated Tablets:
- A core tablet containing rimegepant is surrounded by one or more layers of polymeric coating.
- The coating acts as a barrier, dissolving or eroding after a predetermined period to release the drug rapidly.
- Advantages include ease of manufacturing, reproducible lag times, and suitability for high-dose formulations.[25]

Pulsincaps (Capsule with Hydrogel Plug):
- Comprise a gelatin capsule body filled with the drug core and sealed with a hydrogel or wax plug.
- The plug gradually swells or dissolves, triggering rapid drug release after a controlled lag period.
- Ideal for oral pulsatile delivery and can be tailored to achieve precise time-dependent release.[26]

Time-Dependent Coatings:
- Use polymers such as hydroxypropyl methylcellulose (HPMC), Eudragit, or other hydrophilic/hydrophobic matrices.
- Coatings can be pH-sensitive, swelling-controlled, or erosion-based, allowing for controlled lag times aligned with circadian patterns of migraine.[27]

Selecting the appropriate delivery approach depends on dose, solubility of rimegepant, desired lag time, and patient convenience.

4.2. Polymer Selection

Polymers are a key determinant of lag time precision and burst release behavior:

- Hydrophilic Swellable Polymers:

Swell upon contact with gastrointestinal fluids, gradually breaking the barrier to release the drug.

- Erosion-Based Polymers:

Gradually degrade in the GI tract, allowing the drug core to be exposed after a specific lag period.

- pH-Responsive Polymers:

Dissolve or swell at specific pH values, enabling site-specific release.[28]
The polymer selection must balance mechanical strength, predictability, biocompatibility, and controlled disintegration, ensuring the drug is released only at the targeted time.

4.3. Desired Lag Time and Release Profile

- The lag period should reflect the timing of anticipated migraine attacks for example, night-time dosing with early morning release.
- After the lag phase, the system should produce a burst release sufficient to achieve therapeutic plasma concentrations rapidly, ensuring effective symptom control.
- Optimization of lag time and release profile requires careful calibration of polymer type, coating thickness, and capsule plug composition.[29]

V. DEVELOPMENT AND EVALUATION STRATEGIES

A systematic approach is required to translate the design into a stable, reproducible formulation:

5.1. Preformulation Studies

- Evaluate physicochemical properties of rimegepant, including solubility, pKa, stability, and particle size.
- Assess compatibility with excipients using analytical techniques such as Fourier Transform Infrared Spectroscopy (FTIR) and Differential Scanning Calorimetry (DSC).
- Preformulation studies ensure that the active drug remains stable and effective throughout processing and storage.[30]

5.2. Formulation Optimization

- Employ design of experiments (DOE) techniques, such as Box–Behnken or factorial designs, to optimize polymer ratios, coating thickness, plug dimensions, and compression force.
- DOE helps identify critical factors influencing lag time, release kinetics, and mechanical properties, ensuring reproducibility and robustness.[31]

5.3. In Vitro Characterization

- Lag Time Determination and Dissolution Testing: Using USP dissolution apparatus to simulate gastrointestinal conditions and confirm precise timing and burst release.
- Drug Content Uniformity: Ensures consistent dosing across all units.
- Physical Parameter Validation: Includes hardness, friability, weight variation, and dimensional assessment.
- Stability Studies: Conducted under ICH guidelines to evaluate chemical, physical, and mechanical stability under various storage conditions.[32]

VI. POTENTIAL CHALLENGES AND FUTURE DIRECTIONS

6.1. Translational Challenges

- Consistency Across Batches:

Achieving uniform lag times and reproducible release profiles can be challenging due to variations in coating thickness or polymer properties.

- Patient Compliance:

While PDDS reduces dosing frequency, timing of administration relative to sleep or daily routines may still affect efficacy.

- In Vivo Correlation:

Translating in vitro lag time and release kinetics to predictable in vivo plasma profiles requires careful pharmacokinetic modeling.[33]

6.2. Future Research Opportunities

- Nanoformulation Approaches: Incorporating rimegepant into nanocarrier systems with stimuli-responsive triggers (pH, temperature, enzymes) could allow more precise chronotherapeutic control.
- Clinical Evaluation of Timing-Optimized Regimens: Studies are needed to validate whether time-controlled PDDS improves migraine prevention and acute symptom relief compared to conventional dosing.
- Comparative Pharmacokinetics: Assessing plasma profiles and therapeutic outcomes relative to standard tablets or ODTs will support regulatory approval and clinical adoption.[34]

VII. CONCLUSIONS

Pulsatile drug delivery systems (PDDS) present a strategically advantageous approach for administering rimegepant, particularly in the context of migraine management, where attacks frequently follow predictable circadian patterns. By incorporating a predefined lag period followed by a rapid burst release, PDDS can synchronize the drug's therapeutic action with the onset of migraine attacks, enhancing

efficacy while minimizing unnecessary systemic exposure.

Although direct studies of pulsatile rimegepant formulations are currently sparse, extensive research on PDDS for other chronotherapeutic drugs provides a robust framework for design and evaluation. Principles such as polymer-based lag time control, erosion or swelling-triggered release, and time-specific coatings can be adapted to rimegepant's physicochemical and pharmacokinetic properties.

The potential benefits of a rimegepant PDDS include:

Enhanced therapeutic efficacy: Rapid drug availability at the precise time of migraine onset ensures faster symptom relief and improved control over attack severity.

Chronotherapeutic alignment: Release profiles can be tailored to match the circadian rhythm of migraine occurrence, offering proactive rather than reactive therapy.

Improved patient adherence and convenience: Pre-programmed lag times reduce the need for on-demand dosing, minimizing missed doses and enhancing consistency in therapy.

Reduced systemic side effects: Limiting drug exposure to periods of high therapeutic need reduces unnecessary plasma concentrations outside migraine windows, improving safety.

Overall, the adaptation of PDDS technology for rimegepant holds significant promise for transforming migraine management. By integrating design principles, formulation strategies, and evaluation methodologies, researchers can develop next-generation rimegepant delivery systems that are both chronotherapeutically optimized and patient-centric, potentially improving clinical outcomes and quality of life for migraine sufferers.

REFERENCES

[1] R. B. Lipton, A. Thiry, B. A. Morris, and R. Croop, "Efficacy and safety of rimegepant 75 mg oral tablet, a CGRP receptor antagonist, for the acute treatment of migraine: A randomized, double-blind, placebo-controlled trial," *Journal of Pain Research*, vol. 17, pp. 2431–2441, 2024.

[2] J. Xu and N. Li, "Rimegepant: A review in the acute treatment and preventive treatment of migraine," Journal of Clinical Neuroscience, 2023.

[3] G. Berman, R. Croop, D. Kudrow, P. Halverson, M. Lovegren, A. C. Thiry, et al., "Safety of rimegepant, an oral CGRP receptor antagonist, plus CGRP monoclonal antibodies for migraine," Headache, vol. 60, no. 8, pp. 1734–1742, 2020.

[4] A. Negro and P. Martelletti, "Rimegepant for the treatment of migraine," Drugs Today (Barcelona), vol. 56, no. 12, pp. 769–780, 2020.

[5] National Library of Medicine, "Rimegepant — LiverTox," NCBI Bookshelf, 2024.

[6] X. Li and Q. Wang, "Clinical meta-analysis of rimegepant in acute migraine treatment," Frontiers in Neurology, vol. 14, Art. no. 1205778, 2023.

[7] "Real-world effectiveness and tolerability of rimegepant for acute migraine therapy in Chinese patients," The Journal of Headache and Pain, 2024.

[8] R. Marcus, R. B. Lipton, and R. Croop, "Randomized clinical trials of rimegepant for migraine," Neurotherapeutics, 2019.

[9] L. J. Scott, "Rimegepant: First approval," Drugs, vol. 80, no. 7, pp. 741–746, 2020.

[10] L. Edvinsson, "Mechanisms of CGRP receptor antagonists in migraine therapeutics," Expert Review of Neurotherapeutics, 2024.

[11] R. Sharma, A. Singh, and S. Kumar, "Pulsatile drug delivery system: A review," International Research Journal of Pharmacy, vol. 3, no. 7, pp. 1–5, 2012.

[12] S. Mishra and N. Mishra, "Pulsatile drug delivery system – A review," International Journal of Recent Advances in Multidisciplinary Topics, vol. 3, no. 4, pp. 16–18, 2022.

[13] R. Venkataswamy and L. Nallaguntla, "Review article on pulsatile drug delivery system," Asian Journal of Pharmaceutical and Clinical Research, vol. 14, no. 6, pp. 48–59, 2021.

[14] P. S. Prasanna Kumar and L. Srinivas, "A review on pulsatile drug delivery systems," International Journal of Pharmaceutical Sciences and Research, vol. 14, no. 7, pp. 3246–3254, 2023.

[15] R. Yadav and D. K. Jain, "Pulsatile drug delivery system: A systematic review," International Journal of Pharmaceutical Sciences and Research, vol. 14, no. 1, pp. 129–141, 2023.

[16] A. R. Sharma, B. Raina, P. S. Bajwa, A. Bhargava, and V. Goel, "Pulsatile drug delivery system – A review," Asian Pacific Journal of Health Sciences, vol. 5, no. 3, pp. 260–270, 2018.
[17] A. Singh and B. Raina, "Chronopharmacologic considerations in PDDS," Chronopharmaceutics Journal, 2018.
[18] P. Gupta and R. Bansal, "PDDS in chronotherapeutics," Journal of Controlled Release Advances, 2022.
[19] T. Bussemer, N. A. Peppas, and R. Bodmeier, "Swelling and rupture properties in PDDS," European Journal of Pharmaceutics and Biopharmaceutics, vol. 56, pp. 261–270, 2003.
[20] R. A. Siegel and C. G. Pitt, "Advances in pulsatile drug delivery systems," Journal of Controlled Release, vol. 33, pp. 173–188, 1995.
[21] B. C. Youan, "Time-controlled oral drug delivery," Journal of Controlled Release, vol. 98, pp. 337–353, 2004.
[22] A. Maroni, L. Zema, M. Cerea, and A. Gazzaniga, "Technological aspects of PDDS," Expert Opinion on Drug Delivery, vol. 2, pp. 855–871, 2005.
[23] D. Pozzi, P. Furlani, and A. Gazzaniga, "Multiparticulate pulsatile delivery systems," Journal of Controlled Release, vol. 31, pp. 99–108, 1994.
[24] P. Roy and A. Shahiwala, "Pulsatile drug delivery systems: Formulation approaches," Journal of Controlled Release, vol. 134, pp. 74–80, 2009.
[25] P. Pandey and P. Sharma, "Chronotherapeutic PDDS: Mechanisms and clinical relevance," International Journal of Drug Delivery, 2020.
[26] A. B. Rane, S. G. Gattani, V. D. Kadam, and A. R. Tekade, "Press-coated tablets as pulsatile delivery systems," Chemical and Pharmaceutical Bulletin, vol. 57, no. 11, pp. 1213–1217, 2009.
[27] R. Rashid, M. Ahmad, and M. Zaman, "Press-coated pulsatile aceclofenac tablets," Pharmaceutics, 2022.
[28] Z. Zhang, X. Qi, and X. Li, "Novel PDDS based on acrylic copolymer," International Journal of Pharmaceutics, vol. 462, pp. 66–73, 2014.
[29] V. M. Ala and D. R. B. Reddy, "Formulation and evaluation of pulsatile zafirlukast tablets," Journal of Drug Delivery and Therapeutics, vol. 10, no. 2, pp. 39–83, 2018.
[30] S. Mishra and N. Mishra, "Hydrogel matrices in PDDS," Journal of Advanced Pharmaceutical Research, 2023.
[31] D. Gupta and S. Jain, "Time-dependent polymer coatings for PDDS," International Journal of Pharmaceutics, 2022.
[32] V. R. Patel and V. P. Patel, "Pulsatile drug delivery: Single vs. multi-unit systems," International Journal of Pharmaceutical Sciences and Research, vol. 6, no. 9, pp. 3676–3688, 2015.
[33] M. H. Smolensky, N. A. Peppas, and R. Hermen, "Chronotherapy and circadian drug delivery," Journal of Biological Rhythms, 2019.
[34] M. U. Gillette and A. J. McArthur, "Circadian influences on migraine and therapeutics," Neuroscience and *Biobehavioral Reviews*, 2018.